DelveInsight reports that over five key companies are actively engaged in developing more than five treatment therapies for C-Met Mutated Non-Small Cell Lung Cancer.
C-Met Mutated Non-Small Cell Lung Cancer Overview:
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) is characterized by an overexpression of the C-Met tyrosine kinase receptor, which is commonly present in epithelial cells. Activation of C-Met results in phosphorylation at specific tyrosine residues (Y1003, Y1313, Y1230/1234/1235, Y1349, and Y1365), which triggers several downstream signaling pathways including RAS/ERK, PI3K/AKT, and cSRC kinase pathways. Through SRC activation, C-Met plays a crucial role in driving epithelial-mesenchymal transition, leading to increased levels of hepatocyte growth factor (HGF) and intratumoral C-Met expression—both of which are strongly associated with NSCLC biology and patient prognosis. NSCLC is primarily classified into three subtypes based on cell morphology: squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Key risk factors for developing NSCLC include smoking, exposure to radiation, and contact with harmful substances such as asbestos, arsenic, and chromium.
Request for a detailed insights report on C-Met Mutated Non-Small Cell Lung Cancer pipeline insights
“C-Met Mutated Non-Small Cell Lung Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the C-Met Mutated Non-Small Cell Lung Cancer Therapeutics Market.
Key Takeaways from the C-Met Mutated Non-Small Cell Lung Cancer Pipeline Report
-
DelveInsight’s C-Met Mutated Non-Small Cell Lung Cancer pipeline report highlights an active landscape with over five companies developing more than five therapies for the treatment of C-Met Mutated NSCLC.
-
Leading companies such as Novartis, Apollomics Inc., Abbvie, Janssen Research and Development, and others are exploring new drug candidates to advance treatment options.
-
Notable pipeline therapies under development include EGF-816 (Nazartinib), APL 101 (Bozitinib), among others.
-
In May 2020, Novartis secured FDA approval for Tabrecta, an oral MET inhibitor targeting metastatic NSCLC with MET exon 14 skipping mutations (METex14). This approval was the first of its kind for this specific genetic alteration, with clinical trials showing an overall response rate of 68% in treatment-naïve patients and 41% in those previously treated.
C-Met Mutated Non-Small Cell Lung Cancer Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the C-Met Mutated Non-Small Cell Lung Cancer Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for C-Met Mutated Non-Small Cell Lung Cancer treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the C-Met Mutated Non-Small Cell Lung Cancer market.
Download our free sample page report on C-Met Mutated Non-Small Cell Lung Cancer pipeline insights
C-Met Mutated Non-Small Cell Lung Cancer Emerging Drugs
-
EGF-816 (Nazartinib): Novartis Oncology
-
APL 101 (Bozitinib): Appolomics Inc.
C-Met Mutated Non-Small Cell Lung Cancer Companies
More than five leading companies are actively working on therapies for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC). Notably, firms like Novartis Oncology have drug candidates in mid-to-late stages of development, including Phase III clinical trials.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
C-Met Mutated Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
C-Met Mutated Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging C-Met Mutated Non-Small Cell Lung Cancer Therapies and Key Companies: C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials and advancements
C-Met Mutated Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment
• C-Met Mutated Non-Small Cell Lung Cancer Assessment by Product Type
• C-Met Mutated Non-Small Cell Lung Cancer By Stage
• C-Met Mutated Non-Small Cell Lung Cancer Assessment by Route of Administration
• C-Met Mutated Non-Small Cell Lung Cancer Assessment by Molecule Type
Download C-Met Mutated Non-Small Cell Lung Cancer Sample report to know in detail about the C-Met Mutated Non-Small Cell Lung Cancer treatment market @ C-Met Mutated Non-Small Cell Lung Cancer Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. C-Met Mutated Non-Small Cell Lung Cancer Current Treatment Patterns
4. C-Met Mutated Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. C-Met Mutated Non-Small Cell Lung Cancer Late-Stage Products (Phase-III)
7. C-Met Mutated Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. C-Met Mutated Non-Small Cell Lung Cancer Discontinued Products
13. C-Met Mutated Non-Small Cell Lung Cancer Product Profiles
14. C-Met Mutated Non-Small Cell Lung Cancer Key Companies
15. C-Met Mutated Non-Small Cell Lung Cancer Key Products
16. Dormant and Discontinued Products
17. C-Met Mutated Non-Small Cell Lung Cancer Unmet Needs
18. C-Met Mutated Non-Small Cell Lung Cancer Future Perspectives
19. C-Met Mutated Non-Small Cell Lung Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the C-Met Mutated Non-Small Cell Lung Cancer Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/